Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
28 sept. 2022 06h30 HE
|
Ocugen
Ocugen’s intranasal candidate is one of the world’s most advanced intranasal COVID-19 vaccinesIntranasal vaccine is designed to curb virus transmission and confer protective immunity MALVERN, Pa.,...
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
12 août 2022 07h30 HE
|
Ocugen
MALVERN, Pa., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
29 juil. 2022 07h30 HE
|
Ocugen
MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and...
Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
21 juin 2022 07h00 HE
|
Ocugen
Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults Ocugen has North American...
Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
14 juin 2022 07h00 HE
|
Ocugen
MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies,...
Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
13 juin 2022 07h00 HE
|
Ocugen
MALVERN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell...
Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
18 avr. 2022 07h11 HE
|
Ocugen
• Ocugen responsible for commercialization of COVAXIN™ in Mexico • COVAXIN™, already authorized for emergency use in adults by health regulators in Mexico, has been submitted for Emergency Use...
Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results
25 févr. 2022 07h31 HE
|
Ocugen
U.S. FDA lifts clinical hold on IND application for COVAXIN™ (BBV152), clearing the pathway for Phase 2/3 clinical trial in support of a BLA submissionEngagement with U.S. FDA to advance pediatric EUA...
Ocugen, Inc. to Present at Upcoming H.C. Wainwright Bioconnect Conference
06 janv. 2022 18h03 HE
|
Ocugen
MALVERN, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
Ocugen Provides Business Update and Third Quarter 2021 Financial Results
09 nov. 2021 07h30 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Emergency Use Authorization application filed with the U.S. FDA for the COVID-19 vaccine candidate, COVAXIN™ (BBV152), for children aged 2 – 18...